Trials / Completed
CompletedNCT00684515
Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)
Phase II Study of SCH 530348 in Subjects With Cerebral Infarction
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to assess safety of Vorapaxar when added to standard of care (aspirin) in Japanese subjects with cerebral infarction. The study will assess incidence and tolerability of bleeding, major adverse cardiac events, all adverse events, and effect on expression of markers of inflammation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vorapaxar 2.5 mg | Oral tablets; once daily for 60 days. |
| DRUG | Vorapaxar 1 mg | Oral tablets; once daily for 60 days |
| DRUG | Placebo | oral tablets; once daily for 60 days |
| DRUG | Aspirin 75-150 mg | oral tablets; once daily for 60 days |
Timeline
- Start date
- 2006-09-21
- Primary completion
- 2007-11-08
- Completion
- 2007-11-08
- First posted
- 2008-05-26
- Last updated
- 2018-09-21
- Results posted
- 2014-07-29
Source: ClinicalTrials.gov record NCT00684515. Inclusion in this directory is not an endorsement.